Albany Molecular Research (AMRI) Tops Q3 EPS by 4c

Albany Molecular Research (NASDAQ: AMRI) reported Q3 EPS of $0.17, $0.04 better than the analyst estimate of $0.13. Revenue for the quarter came in at $151.7 million versus the consensus estimate of $160.75 million.

For earnings history and earnings-related data on Albany Molecular Research (AMRI) click here.

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• Alto Neuroscience, Inc. (ANRO) Tops Q2 EPS by 10c
• FGI Industries Ltd (FGI) Tops Q2 EPS by 59c